Two of the previous studies did not detail the patients’ history of BC, but Srivastava et al. reported a significant difference in expression of UCA1 in recurrent tumours compared to primary tumours (p < 0.001), emphasizing the necessity to analyse patients with recurrent BC separately when evaluating a novel biomarker (Srivastava et al. 2014). Here, UCA1 is linked to neoplasm.